Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Times of India
The Times of India
Lifestyle
TOI Lifestyle Desk | etimes.in

TOI Health News Morning Briefing| AstraZeneca's anti-cancer drug withdrawn in India, preventing dehydration in 50s, signs of heatstroke, role of fish oil supplements in cardiovascular health and more

DCGI orders withdrawal of AstraZeneca's cancer drug due to potential adverse effects

The Drug Controller General of India (DCGI) has instructed all state drug regulators to withdraw AstraZeneca's anti-cancer drug Olaparib tablets. Primarily used to treat patients with gBRCA mutations in advanced ovarian and breast cancer, this drug has been found to have potential adverse effects, according to the DCGI.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.